GeneDx keeps 2026 sales outlook intact despite softer exome and genome expectations
The genetic testing group posted $123.1m of third-quarter revenue and held its full-year range, even as it cut its growth targets for its two flagship sequencing products.
GeneDx Holdings (Nasdaq: WGS) reported $123.1m of revenue for the third quarter of 2026 on 9 November, and left its full-year revenue range at $475m to $490m. The same update, however, brought lower targets for how quickly exome and genome testing will grow, in both volume and revenue.
Profitability figures were mixed. The company reported adjusted net income of $8.6m, while its GAAP net loss came to $12.3m.
The unchanged top-line range alongside reduced growth goals for exome and genome work points to a company adjusting the expected mix of its business rather than its overall sales ambition. The summary available to CompePharma does not give the new target figures, the reasons for the revision, or which parts of the business make up the difference, so the cause cannot be established from the information at hand.
GeneDx also pointed to two commercial developments. Medicaid coverage for whole genome sequencing now reaches 25 states, a measure of public-payer reimbursement for the test. The company also announced new sponsored testing programmes with Mirum and Beren. Terms of those programmes were not provided.
Why it matters
- Holding the $475m to $490m range while trimming exome and genome growth targets suggests the company expects other parts of its business, or other factors, to cover the gap; the reasons were not disclosed.
- Medicaid coverage of whole genome sequencing in 25 states is a data point for market-access teams tracking public-payer reimbursement of genomic testing.
- Sponsored programmes with Mirum and Beren indicate continued company involvement in testing linked to rare disease, though financial and operational terms are not available.
- Readers should consult the full results release for the revised guidance figures before drawing conclusions.
Company's press release (SEC filing): GeneDx Holdings Corp. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
